Novo Nordisk shares rise 8% after Wegovy obesity pill has ‘solid’ launch
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026.George Frey | Bloomberg ...
Tag: Nordisk
Novo Nordisk debuts Wegovy weight-loss pill in the U.S.
A pill form of weight-loss drug Wegovy, manufactured by Danish drugmaker Novo Nordisk, is now available in the U.S., giving ...
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk, ...
Millions more Americans could access obesity drugs after Trump’s deals with Eli Lilly, Novo Nordisk
US President Donald Trump makes an announcement in the Oval Office of the White House in Washington, DC on Nov. ...
Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s
Shares of Eli Lilly and Novo Nordisk dropped Friday, after President Donald Trump said his administration aims to cut the ...
Novo Nordisk halts Wegovy sales on Hims & Hers, claiming
Novo Nordisk is pulling the plug on its partnership with Hims & Hers Health over claims that the telehealth company ...
Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs
Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg | Getty ImagesOnly ...
Novo Nordisk CEO Lars Jorgensen, who led company into weight loss drugs, to step down
People using weight loss drugs like Ozempic and Wegovy drink less People using weight loss drugs like Ozempic and Wegovy ...
Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 18%
The "Wegovy" brand slimming syringe is sold in the Achat pharmacy in Mitte. The "Wegovy" slimming syringe has been available ...
Novo Nordisk CEO attends crisis talks with Danish PM amid Trump’s Greenland threats
Bosses from Fortune 500 Europe companies including Novo Nordisk, Lego, and Carlsberg met with the PM as Trump ups his ...
